Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $200
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $204 to $200.
Alnylam’s Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
The FDA approved a label expansion for Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY) for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now…
Jefferies Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $232
Jefferies analyst Maury Raycroft maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $218 to $232.
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Alnylam Presents Additional Results From The APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy At Heart Failure Society Of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis –
– Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging,
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) from $225 to $250. The analyst says that the company…
Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD for nonalcoholic steatohepatitis…